Leadership

  • Prof Miles Prince
  • Dr Andrew See
  • A/Prof Robert Rome
  • A/Prof Joe McKendrick
  • Dr Peter Sherwen

Highlights

  • Epworth is the leading provider of stereotactic treatment in Australia, a technology suitable for tumours and cancers up to a specified maximum size. The technology is also used to treat non-cancerous medical conditions such as Parkinson’s disease and is currently being trialled as a treatment in certain types of prostate cancers and brain cancers. Epworth is recognised as a leader in this technology
  • Epworth is the most active centre of robotic surgery in the country, with 3 robot-equipped theatres at Epworth Eastern, Epworth Freemasons and Epworth Richmond. Epworth has seen more than 5,000 robotic procedures performed by its 50 robotic qualified surgeons since 2003 and has a dedicated Centre for Robotic Surgery
  • The creation of a new Professorial Chair of Molecular Oncology and Cancer Immunology and appointment of Professor Miles Prince AM MBBS (Hons) MD FRACP FRCPA MACD AFRACMA as Professor/Director to lead this area. This new academic unit at Epworth Freemasons provides research, clinical and teaching leadership in molecular oncology and cancer immunology within the School of Medicine at the University of Melbourne

Our performance

Radiotherapy waiting time is the number of days from when the patient is ready to be treated until the day the patient first receives radiotherapy treatment. Reported waiting times include weekends and public holidays and days on which a unit was unable to provide services.

The Royal Australian and New Zealand College of Radiologists (RANZCR) has defined four key benchmarks related to the delivery of radiation oncology.

The National Radiotherapy Waiting Times Database (NRWTD) collates data provided to the Australian Institute of Health and Welfare (AIHW) by state and territory health authorities, and some private radiotherapy providers, based on the data set specification (DSS) for radiotherapy waiting times.

Activity

The figures below are for patients admitted by an oncologist. Patients may also be admitted for surgery as treatment for their cancer, and figures relating to these patients are included.

FY 2018

 

Services Admissions

Chemotherapy

18,673

Condition treated

  • Breast cancer
  • Bladder cancer
  • Bowel cancer
  • Digestive system cancers
  • Central nervous system cancers
  • Gynaecological cancers
  • Head and neck cancers
  • Kidney cancer
  • Leukaemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Pancreatic cancer
  • Prostate cancer
  • Renal and urinary tract cancers
  • Skin cancer
  • Stomach cancer
  • Testicular cancer

Services

  • c
  • h
  • m
  • r